-->

Stereotactic radiotherapy for lung cancer that cannot be surgically removed

Stereotactic body radiation therapy

Stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy (SABR). Since its application in the mid-1990s, SBRT has distinguished itself in the radical treatment of most tumors because of its high tumor control rate, good tolerance of normal tissues, long survival time and extremely convenient patients. Early lung cancer has become a beneficiary of this technology. SBRT is an effective low-segment non-invasive ablation treatment that can be performed in an outpatient clinic. It is usually treated 1-5 times, once a day or every other day.

The EDGE radiosurgery system applied by Henry Ford Hospital in the United States is a generation of SBRT. It is the most cutting-edge non-invasive tumor clearing technology to date. It can shorten the radiotherapy treatment time for lung cancer to 10-15 minutes, and the entire treatment is completed in 5 days. . Most patients can return to normal life immediately after treatment.

SBRT for lung cancer that cannot be surgically removed

RTOG 0236 is the first multi-center clinical study in North America to treat SBRT for clinically inoperable early lung cancer. The RTOG 0236 clinical study started in 2004 and treated 57 patients in total. In 2006, patients were enrolled. The clinical results are quite good: the 3-year primary tumor control rate reaches 98%, and the survival rate is 56%.

Applying SBRT to surgically resected lung cancer

The treatment results of SBRT for inoperable lung cancer show that it can effectively eliminate the primary tumor, and the tolerance is also better in this part of high-risk population. In view of this, the possibility of its application in patients with operable lung cancer has received attention. The clinical results show that as long as a reasonable radiation dose is given, SBRT treatment can obtain a therapeutic effect that is quite close to that of surgical resection or even lobectomy.

Speed ​​front knife is the most advanced SBRT treatment technology to date

The EDGE tumor noninvasive radiosurgery treatment system is a cancer treatment system approved by the US FDA in 2014. It is by far the most effective tumor radiosurgery system. It is difficult to perform routine surgery on tumors such as head tumors, lung cancer, and spine tumors. , Liver cancer and other solid tumors have treatment effects that are difficult to achieve with conventional surgery and radiotherapy equipment, and are the best choice for cancer patients to remove tumor lesions so far.

Since April 2014, the world’s first EDGE tumor noninvasive radiotherapy system has been operating in the entire system of Henry Ford Hospital in the United States. It has treated more than 400 tumor patients, and the treatment satisfaction rate (Tumor Co ntrol Rate) is greater than 95%. And no adverse reactions occurred. Among these tumor patients, brain tumors (including primary and metastatic brain tumors) accounted for 31%, lung cancer accounted for 29%, spinal tumors accounted for 23%, gastrointestinal tumors accounted for 9%, and adrenal cancer accounted for 7%.

Susan Hau
Website |  + posts

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

  • Comments Closed
  • April 10th, 2020

Instructions for using Opdivo -nivolumab for patients with non-small cell lung cancer

Previous Post:
nxt-post

Multiple genetic testing of lung cancer tumors

Next Post:

Scan the code